The brief

Analyst view

• CARVYKTI: $657M Q2 2026 sales (+50% YoY) at 348 sites in 19 markets; best-selling CAR-T.
• First company-wide profitability in Q2 2026; $63M adjusted net income, expected through H2.
• LB2501 in vivo CAR-T: 83.3% complete-response rate; IND filing planned by end of 2026.

Technical approach

As reported

CAR-T Technology

Engineered T-cell therapy

CARVYKTI is a chimeric antigen receptor (CAR) T-cell therapy that modifies a patient's T cells to recognize and attack cancer cells expressing the BCMA antigen.

Manufacturing Scale

Scaled manufacturing and distribution

Legend has built manufacturing and distribution infrastructure to support global supply, now present in 348 treatment sites across 19 markets.

Next-Generation Pipeline

In vivo CAR-T development

LB2501 is an in vivo CAR-T therapy that generates CAR-T cells within the patient's body, potentially simplifying manufacturing and administration.